Tenderwize
Zurück zur Suche

Open-House discount agreements for Eribulin

AOK Niedersachsen. Die Gesundheitskasse.·Hannover, Germany·Deadline Aug 21, 2027 · 361 days left·Open·Supplies·Framework
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open-House Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V Eribulin, ATC L01XX41 - Vertragsregionen Niedersachsen, Bremen und Sachsen-Anhalt

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

The notice requires handwritten signatures on paper originals, while only the separate file is sent by email. Missing t...

Eligibility is limited to pharmaceutical undertakings under the AMG, or a consortium of such undertakings, and local re...

No procurement documents available

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2027
  • Supply-related Open-House discount agreements for the active substance Eribulin (ATC L01XX41).
  • Applies to parenteral preparations from finished medicinal products used in oncology for immediate physician administration.
Vollständige Zusammenfassung anzeigen

Open-House framework-style pharmaceutical supply arrangement for Eribulin (ATC L01XX41) in Germany, covering the regions Niedersachsen/Bremen and Sachsen-Anhalt. The notice states that identical, non-exclusive discount agreements will be offered to all interested pharmaceutical companies that meet the stated eligibility conditions. Electronic submission is not allowed; signed paper originals and a separate file must be submitted. No contract value is stated.

Risiken

The notice requires handwritten signatures on paper originals, while only the separate file is sent by email. Missing t...

Eligibility is limited to pharmaceutical undertakings under the AMG, or a consortium of such undertakings, and local re...

No procurement documents available

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of § 4 Abs. 18 AMG, or a consortium of pharmaceutical undertakings, for the offered medicinal products.
  • The company must have its seat in Germany, another EU Member State, or another EEA State, as stated in the notice.
  • Local representatives may participate only if they themselves qualify as pharmaceutical undertakings for the offered products.

Zuschlagskriterien

Lot 1

Price criterion stated, but no weight or further detail provided.

Auftraggeber

Lose (1)

LOT-0000

Open-House discount agreements for Eribulin

Open-House non-exclusive discount agreements for Eribulin, ATC L01XX41, for parenteral preparations used in oncology for immediate physician administration. The notice says the agreements are offered for two regional lots: Lot 1 Niedersachsen/Bremen and Lot 2 Sachsen-Anhalt. Lot-specific value, CPV, and deadline details are not separately provided in the structured data.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE929, Germany

Dauer

Oct 2025 - Oct 2027

Kategorie

Pharmaceutical products

Zuschlagskriterien

Price

Frist

Deadline Aug 21, 2027

Vergabedetails

Veröffentlichungsdatum
02 Sep 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
573935-2025

Ähnliche Ausschreibungen